Melvin L.K. Chua, FRCR, PhD, FASCO, on validation of an MMAI model in Asian patients
Data presented at the American Society for Radiation Oncology 67th Annual Meeting validated the performance of the ArteraAI P [...]
AI Tools Speed Prostate Cancer Decisions With Faster Results
FDA-authorized artificial intelligence (AI) tools have the potential to help patients with prostate cancer get clearer answer [...]
AI Model Identifies STAMPEDE Patients Needing Treatment Intensification – Nicholas James
Zachary Klaassen interviews Nicholas James about applying the ArteraAI prostate test to high-risk M0 prostate cancer patients [...]
AI News: Artera presented data at #ASCO25 showing that its AI platform can identify prostate cancer patients most likely to benefit (or not benefit) from added androgen receptor inhibitor therapy
CMO Tim Showalter describes the finding, which was selected as a "Best of ASCO" oral presentation. Plus, helping to determine [...]
AI-Enabled Selection of Patients for Benefit of ADT + ARPI
Dr. Nick James discusses intriguing data from STAMPEDE on the use of AI to analyze pathology slides and predict benefit from [...]
Multimodal AI Test Predicts Prostate Cancer Metastasis and Treatment Response – Timothy Showalter
Leslie Ballas speaks with Timothy Showalter about a multimodal artificial intelligence-based prostate cancer test. Dr. Showal [...]
Podcast: Prognostic Artificial Intelligence Scores and Outcomes in Nonmetastatic Prostate Cancer
JCO PO author Dr. Timothy Showalter at Artera and University of Virginia shares insights into his JCO PO article, “Digital Pa [...]
The Future of AI in Urology
Artificial intelligence (AI) has become a disruptor in nearly every sector, including health care. In a recent interview with [...]
How ArteraAI is changing prostate cancer treatment through AI-powered diagnostics
Roupen Odabashian, Internal Medicine Physician and Hematology/Oncology Fellow at Karmanos Cancer Institute, shared a post on [...]